Fahlbusch R, Thapar K
Department of Neurosurgery, University of Erlangen-Nürnberg, Germany.
Baillieres Best Pract Res Clin Endocrinol Metab. 1999 Oct;13(3):471-84. doi: 10.1053/beem.1999.0034.
Despite ongoing advances in the pharmacological, radiotherapeutic and endocrine management of pituitary tumours, surgery remains the therapy of choice for the large majority of these lesions. As surgical efficacy is now being judged by more rigorous technical standards and by more stringent endocrine criteria than ever before, such scrutiny has only served to reinforce the fundamental role of surgery in pituitary tumour management. With the revival of the trans-sphenoidal approach, together with its ongoing technical evolution during the past three decades, pituitary tumours have emerged as eminently treatable lesions, with trans-sphenoidal microsurgery affording long-term, high-quality survival in many patients. Pituitary surgery is, however, not without limitation or liability. Even in experienced hands, endocrine and/or oncological remission is not uniformly achieved. Moreover, of those patients in whom such 'cures' can be induced, the durability of the response is not absolute, as tumour recurrence will continue to threaten a small but significant proportion of patients over time. Finally, and notwithstanding the fact that trans-sphenoidal surgery remains one of the safest procedures in contemporary, neurosurgical practice, complications can occur, some of which can be associated with significant morbidity and, on rare occasions, mortality. Clearly, there continue to be areas in need of improvement, and it has been in response to these limitations of contemporary pituitary surgery that neurosurgeons have sought to develop alternative strategies to improve surgical outcome. As a result, a variety of important innovations have been introduced during recent years. Among others, the most important and effective of these have been the application of neuronavigational techniques, trans-sphenoidal endoscopy and intraoperative MR resection control to the standard trans-sphenoidal approach to pituitary tumours. Whereas some advances are conceptual and others are technical, all are helping to push the limits of pituitary surgery to new frontiers of efficacy and safety. In this chapter, the current state of the art of pituitary surgery is reviewed along with those important new developments that, in the foreseeable future, hope to improve the quality of surgical care available to the pituitary tumour patient.
尽管垂体瘤的药物治疗、放射治疗和内分泌治疗不断取得进展,但对于大多数此类病变而言,手术仍然是首选治疗方法。由于目前判断手术疗效所依据的技术标准比以往更加严格,内分泌标准也更加苛刻,这种严格审查只是进一步强化了手术在垂体瘤治疗中的基础作用。随着经蝶窦入路的复兴,以及在过去三十年中其技术的不断发展,垂体瘤已成为极易治疗的病变,经蝶窦显微手术使许多患者获得了长期的高质量生存。然而,垂体手术并非没有局限性或风险。即使是经验丰富的医生,也不能始终实现内分泌和/或肿瘤学缓解。此外,在那些能够诱导实现这种“治愈”的患者中,反应的持久性也不是绝对的,因为随着时间的推移,肿瘤复发仍会威胁到一小部分但相当数量的患者。最后,尽管经蝶窦手术仍然是当代神经外科手术中最安全的手术之一,但仍可能发生并发症,其中一些可能导致严重的发病率,在极少数情况下还会导致死亡。显然,仍有需要改进的领域,正是针对当代垂体手术的这些局限性,神经外科医生一直在寻求开发替代策略以改善手术效果。因此,近年来引入了各种重要的创新方法。其中,最重要且最有效的是将神经导航技术、经蝶窦内镜检查和术中磁共振切除控制应用于垂体瘤的标准经蝶窦手术入路。有些进展是概念性的,有些是技术性的,但所有这些都有助于将垂体手术的极限推向疗效和安全性的新前沿。在本章中,将回顾垂体手术的当前技术水平以及那些在可预见的未来有望提高垂体瘤患者手术治疗质量的重要新进展。